BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Panteris V, Perdiou A, Tsirimpis V, Karamanolis DG. Acute coronary syndrome after infliximab therapy in a patient with Crohn’s disease. World J Gastroenterol 2006; 12(38): 6235-6238 [PMID: 17036404 DOI: 10.3748/wjg.v12.i38.6235]
URL: https://www.wjgnet.com/1007-9327/full/v12/i38/6235.htm
Number Citing Articles
1
Sumeet Gandhi, Neeraj Narula, John K. Marshall, Michael Farkouh. Are Patients with Inflammatory Bowel Disease at Increased Risk of Coronary Artery Disease?The American Journal of Medicine 2012; 125(10): 956 doi: 10.1016/j.amjmed.2012.03.015
2
SreyRam Kuy, Anahita Dua, Rohit Chappidi, Gary Seabrook, Kellie R Brown, Brian Lewis, Peter J Rossi, Cheong J Lee. The increasing incidence of thromboembolic events among hospitalized patients with inflammatory bowel diseaseVascular 2015; 23(3): 260 doi: 10.1177/1708538114541799
3
Ravi Rasalingam, Ibrahim M. Saeed, Pamela K. Woodard, Julio E. Pérez. Left Ventricular Thrombus in the Setting of Normal Left Ventricular Function in Patients with Crohn's DiseaseEchocardiography 2016; 33(1): 145 doi: 10.1111/echo.13081
4
Current awareness: Pharmacoepidemiology and drug safetyPharmacoepidemiology and Drug Safety 2007; 16(5) doi: 10.1002/pds.1374
5
Charles N. Bernstein, Andre Wajda, James F. Blanchard. The Incidence of Arterial Thromboembolic Diseases in Inflammatory Bowel Disease: A Population-Based StudyClinical Gastroenterology and Hepatology 2008; 6(1): 41 doi: 10.1016/j.cgh.2007.09.016
6
Juri Tatsuoka, Takahiro Igarashi, Ryuta Kajimoto, Masato Kobayashi, Nobuhiro Moro, Takeshi Suma, Hideki Oshima, Atsuo Yoshino. High-dose-infliximab-associated Cerebral Venous Sinus Thrombosis: A Case Report and Review of the LiteratureInternal Medicine 2021; 60(16): 2677 doi: 10.2169/internalmedicine.6447-20
7
Ashok Kumar, Tapan Ghose, Naval Mendiratta, Pradip K. Prajapati, Anil Abrol. Acute coronary syndrome caused by infliximab in a patient with ankylosing spondylitisInternational Journal of Rheumatic Diseases 2013; 16(2): 235 doi: 10.1111/1756-185X.12052
8
Soner Senel, Veli Cobankara, Ozgur Taskoylu, Aydin Guclu, Harun Evrengul, Mehmet Gungor Kaya. Effect of Infliximab Treatment on QT Intervals in Patients with Ankylosing SpondylitisJournal of Investigative Medicine 2011; 59(8): 1273 doi: 10.2310/JIM.0b013e3182330720
9
Dimitri Renard, Luc Cornillet, Giovanni Castelnovo. Myocardial infarction after rituximab infusionNeuromuscular Disorders 2013; 23(7): 599 doi: 10.1016/j.nmd.2013.03.014
10
Martin Rebolledo Del Toro, Camila Borda, Luisa Fernanda Rincón, Andrea Castillo, Daniel Gerardo Fernández-Ávila. Síndrome coronario agudo recurrente tras infusión de infliximab en paciente con artritis reumatoideColombia Medica 2023; 54(2): e5005466 doi: 10.25100/cm.v54i2.5466
11
Lindsey Sellers Coppiano, Dianne May. A Worldwide Yearly Survey of New Data in Adverse Drug ReactionsSide Effects of Drugs Annual 2022; 44: 379 doi: 10.1016/bs.seda.2022.09.012
12
Pietro Enea Lazzerini, Pier Leopoldo Capecchi, Mauro Galeazzi, Franco Laghi-Pasini. Biologic drugs and arrhythmic risk in chronic inflammatory arthritis: the good and the badImmunologic Research 2017; 65(1): 262 doi: 10.1007/s12026-016-8833-7
13
Nadine Petitpain, Nathalie Bornert-Keller, Laurent Peyrin-Biroulet. Acute coronary syndrome in a Crohn's disease patient treated with adalimumabJournal of Crohn's and Colitis 2013; 7(9): e396 doi: 10.1016/j.crohns.2013.02.011
14
Sudeep D. Thapa, Hiba Hadid, Waseem Imam, Jason Schairer, Syed-Mohammed Jafri. Effect of Inflammatory Bowel Disease–Related Characteristics and Treatment Interventions on Cardiovascular Disease IncidenceThe American Journal of the Medical Sciences 2015; 350(3): 175 doi: 10.1097/MAJ.0000000000000535
15
C. Lê Quang, M. Kouzez, C. Welsch, R. Ravan, N. Ferrier, P. Cassan, X. Marcaggi, G. Amat. Myopéricardite ou nécrose sous-endocardique : apport de l’imagerie par résonance magnétique illustré par un cas cliniqueAnnales de Cardiologie et d'Angéiologie 2008; 57(5): 307 doi: 10.1016/j.ancard.2008.08.009